Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences (RNA) Return on Equity (2020 - 2025)

Avidity Biosciences (RNA) has disclosed Return on Equity for 6 consecutive years, with 0.38% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity fell 16.0% year-over-year to 0.38%, compared with a TTM value of 0.38% through Dec 2025, down 16.0%, and an annual FY2025 reading of 0.44%, down 10.0% over the prior year.
  • Return on Equity was 0.38% for Q4 2025 at Avidity Biosciences, down from 0.36% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.21% in Q3 2024 and bottomed at 0.43% in Q3 2022.
  • Average Return on Equity over 5 years is 0.32%, with a median of 0.34% recorded in 2022.
  • The sharpest move saw Return on Equity crashed -55bps in 2021, then grew 20bps in 2024.
  • Year by year, Return on Equity stood at 0.3% in 2021, then decreased by -20bps to 0.36% in 2022, then decreased by -14bps to 0.42% in 2023, then soared by 47bps to 0.22% in 2024, then crashed by -74bps to 0.38% in 2025.
  • Business Quant data shows Return on Equity for RNA at 0.38% in Q4 2025, 0.36% in Q3 2025, and 0.36% in Q2 2025.